Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition
- 22 May 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Gene Therapy
- Vol. 15 (21), 1411-1423
- https://doi.org/10.1038/gt.2008.90
Abstract
In human gene therapy applications, lentiviral vectors may have advantages over γ-retroviral vectors in several areas, including the ability to transduce nondividing cells, resistance to gene silencing and a potentially safer integration site profile. However, unlike γ-retroviral vectors it has been problematic to drive the expression of multiple genes efficiently and coordinately with approaches such as internal ribosome entry sites or dual promoters. Using different 2A peptides, lentiviral vectors expressing two-gene T-cell receptors directed against the melanoma differentiation antigens gp100 and MART-1 were constructed. We demonstrated that addition of amino-acid spacer sequences (GSG or SGSG) before the 2A sequence is a prerequisite for efficient synthesis of biologically active T-cell receptors and that addition of a furin cleavage site followed by a V5 peptide tag yielded optimal T-cell receptor gene expression. Furthermore, we determined that the furin cleavage site was recognized in lymphocytes and accounted for removal of residual 2A peptides at the post-translational level with an efficiency of 20–30%, which could not be increased by addition of multiple furin cleavage sites. The novel bicistronic lentiviral vector developed herein afforded robust anti-melanoma activities to engineered peripheral blood lymphocytes, including cytokine secretion, cell proliferation and lytic activity. Such optimal vectors may have immediate applications in cancer gene therapy.Keywords
This publication has 55 references indexed in Scilit:
- T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma ModelJournal of Immunotherapy, 2008
- Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytesBlood, 2007
- Improving Transcriptional Termination of Self-inactivating Gamma-retroviral and Lentiviral VectorsMolecular Therapy, 2007
- Enhanced Antitumor Activity of T Cells Engineered to Express T-Cell Receptors with a Second Disulfide BondCancer Research, 2007
- Gene transfer in humans using a conditionally replicating lentiviral vectorProceedings of the National Academy of Sciences of the United States of America, 2006
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Enhanced Antitumor Activity of Murine-Human Hybrid T-Cell Receptor (TCR) in Human Lymphocytes Is Associated with Improved Pairing and TCR/CD3 StabilityCancer Research, 2006
- Stable antibody expression at therapeutic levels using the 2A peptideNature Biotechnology, 2005
- Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide–based retroviral vectorNature Biotechnology, 2004
- Chromosomal position or virus mutation permits retrovirus expression in embryonal carcinoma cellsCell, 1986